肛管鳞状细胞癌放疗后18F-FDG PET/CT评估的预后价值:来自法国多中心队列FFCD-ANABASE的患者
本研究基于法国多中心队列FFCD-ANABASE,纳入388例接受放疗或放化疗的局限性肛管鳞状细胞癌患者,评估放疗后18F-FDG PET/CT定性评估对无复发生存(RFS)、无结肠造口生存(CFS)和总生存(OS)的预后价值。结果显示,完全代谢反应(CMR)患者3年RFS、CFS和OS均显著优于非CMR患者(P<0.0001)。定量参数在154例患者中分析,基线及治疗后部分参数与3年RFS显著相关。
要点
- 388例局限性肛管鳞状细胞癌患者放疗后4-6个月行18F-FDG PET/CT,中位随访35.5个月。
- CMR患者3年RFS、CFS、OS分别为84.2%、84.7%、88.6%,均显著优于非CMR患者(P<0.0001)。
- 定量参数(如基线SUVmax、MTV等)与3年RFS显著相关,但需进一步试验评估。
核心结论
- 放疗后18F-FDG PET/CT评估的治疗反应对肛管鳞状细胞癌具有显著预后价值。
- 18F-FDG PET/CT可能有助于调整随访策略,尤其是局部晚期肿瘤患者。
- 定量参数可识别预后较差的患者,但应在进一步试验中评估。
研究设计与样本
- 研究为法国多中心队列FFCD-ANABASE的连续患者分析,纳入2015年1月至2020年4月接受治疗的1015例患者中388例(300女、88男)来自36个中心。
- 纳入标准为局限性肛管鳞状细胞癌,在基线及放疗或放化疗后4-6个月接受18F-FDG PET/CT检查。
- 中位年龄65岁(范围32-90岁);早期肿瘤147例(37.9%),局部晚期241例(62.1%);59例(15.2%)接受放疗,329例(84.8%)接受放化疗。
- 定性评估将患者分为完全代谢反应(CMR)和非CMR;定量参数在基线和治疗后18F-FDG PET/CT上测量。
- 采用Kaplan-Meier法分析RFS、CFS和OS,采用单因素和多因素Cox回归分析关联。
主要发现
- 中位随访35.5个月(95%CI 32.8-36.6个月)。
- CMR患者3年RFS为84.2%(95%CI 77.8%-88.9%),非CMR患者为42.1%(95%CI 33.4%-50.6%),P<0.0001。
- CMR患者3年CFS为84.7%(95%CI 77.2%-89.3%),非CMR患者为47.9%(95%CI 38.1%-56.8%),P<0.0001。
- CMR患者3年OS为88.6%(95%CI 82.5%-92.7%),非CMR患者为63.5%(95%CI 53.2%-72.1%),P<0.0001。
- 定量参数在来自3个中心的154例患者中可用;与3年RFS显著相关的参数包括基线SUVmax(原发肿瘤[T])HR 1.05(95%CI 1.01-1.1;P=0.018)、SUVpeak(T)HR 1.09(95%CI 1.02-1.15;P=0.007)、MTV 41%(T)HR 1.02(95%CI 1-1.03;P=0.023)、MTV 41%(淋巴结[N])HR 1.06(95%CI 1.03-1.1;P<0.001)、MTV 41%(T+N)HR 1.02(95%CI 1-1.03;P=0.005)和治疗后SUVmax HR 1.21(95%CI 1.09-1.34;P<0.001)。
关键数值与推荐
- 定性评估以完全代谢反应(CMR)与非CMR分组,CMR组3年RFS、CFS、OS均显著优于非CMR组(P<0.0001)。
- 定量参数中,基线SUVmax(T)每增加1单位,3年RFS风险HR 1.05(95%CI 1.01-1.1;P=0.018)。
- 基线SUVpeak(T)HR 1.09(95%CI 1.02-1.15;P=0.007);MTV 41%(T)HR 1.02(95%CI 1-1.03;P=0.023)。
- MTV 41%(N)HR 1.06(95%CI 1.03-1.1;P<0.001);MTV 41%(T+N)HR 1.02(95%CI 1-1.03;P=0.005)。
- 治疗后SUVmax HR 1.21(95%CI 1.09-1.34;P<0.001)。
临床怎么用
- 作者认为,放疗后18F-FDG PET/CT评估的治疗反应具有显著预后价值,可能有助于调整随访策略,尤其是局部晚期肿瘤患者。
- 作者认为,定量参数可识别预后较差的患者,但应在进一步试验中评估。
局限性
- 定量参数仅在来自3个中心的154例患者中可用。
- 作者指出定量参数应在进一步试验中评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study aimed to evaluate the prognostic value of 18F-FDG PET/CT qualitative assessment in terms of recurrence-free survival (RFS), colostomy-free survival (CFS), and overall survival (OS) after radiation therapy (RT) of squamous cell carcinoma of the anus (SCCA). Secondary objectives were to evaluate the prognostic value of baseline and posttherapeutic quantitative 18F-FDG PET/CT parameters in terms of RFS, CFS, and OS. Methods: We included all consecutive patients from the French multicentric cohort FFCD-ANABASE who had undergone 18F-FDG PET/CT at baseline and 4-6 mo after RT or chemoradiotherapy for a localized SCCA. Qualitative assessments separated patients with complete metabolic response (CMR) and non-CMR. Quantitative parameters were measured on baseline and posttreatment 18F-FDG PET/CT. RFS, CFS, and OS were analyzed using the Kaplan-Meier method. Associations among qualitative assessments, quantitative parameters, and RFS, CFS, and OS were analyzed using univariate and multivariate Cox regression. Results: Among 1,015 patients treated between January 2015 and April 2020, 388 patients (300 women and 88 men) from 36 centers had undergone 18F-FDG PET/CT at diagnosis and after treatment. The median age was 65 y (range, 32-90 y); 147 patients (37.9%) had an early-stage tumor and 241 patients (62.1%) had a locally advanced-stage tumor; 59 patients (15.2%) received RT, and 329 (84.8%) received chemoradiotherapy. The median follow-up was 35.5 mo (95% CI, 32.8-36.6 mo). Patients with CMR had better 3-y RFS, CFS, and OS, at 84.2% (95% CI, 77.8%-88.9%), 84.7% (95% CI, 77.2%-89.3%), and 88.6% (95% CI, 82.5%-92.7%), respectively, than did non-CMR patients, at 42.1% (95% CI, 33.4%-50.6%), 47.9% (95% CI, 38.1%-56.8%), and 63.5 (95% CI, 53.2%-72.1%), respectively (P < 0.0001). Quantitative parameters were available for 154 patients from 3 centers. The following parameters were statistically significantly associated with 3-y RFS: baseline SUVmax (primitive tumor [T]) (hazard ratio [HR], 1.05 [95% CI, 1.01-1.1; P = 0.018]), SUVpeak (T) (HR, 1.09 [95% CI, 1.02-1.15; P = 0.007]), MTV 41% (T) (HR, 1.02 [95% CI, 1-1.03; P = 0.023]), MTV 41% (lymph node [N]) (HR, 1.06 [95% CI, 1.03-1.1; P < 0.001]), MTV 41% (T + N) (HR, 1.02 [95% CI, 1-1.03; P = 0.005]), and posttreatment SUVmax (HR, 1.21 [95% CI, 1.09-1.34; P < 0.001]). Conclusion: Treatment response assessed by 18F-FDG PET/CT after RT for SCCA has a significant prognostic value.18F-FDG PET/CT could be useful for adapting follow-up, especially for patients with locally advanced-stage tumors. Quantitative parameters could permit identification of patients with a worse prognosis but should be evaluated in further trials.
引用
- Combet-Curt V, Buchalet C, Le Malicot K, et al. Prognostic Value of 18F-FDG PET/CT Assessment After Radiotherapy of Squamous Cell Carcinoma of the Anus in Patients from the National Multicentric Cohort FFCD-ANABASE. J Nucl Med. 2024. PMID: 38936973. doi:10.2967/jnumed.124.267626
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。